440 related articles for article (PubMed ID: 14515277)
1. Molecular characterization of the chemokine receptor CXCR3: evidence for the involvement of distinct extracellular domains in a multi-step model of ligand binding and receptor activation.
Xanthou G; Williams TJ; Pease JE
Eur J Immunol; 2003 Oct; 33(10):2927-36. PubMed ID: 14515277
[TBL] [Abstract][Full Text] [Related]
2. CCR3 functional responses are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11.
Xanthou G; Duchesnes CE; Williams TJ; Pease JE
Eur J Immunol; 2003 Aug; 33(8):2241-50. PubMed ID: 12884299
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist.
Heise CE; Pahuja A; Hudson SC; Mistry MS; Putnam AL; Gross MM; Gottlieb PA; Wade WS; Kiankarimi M; Schwarz D; Crowe P; Zlotnik A; Alleva DG
J Pharmacol Exp Ther; 2005 Jun; 313(3):1263-71. PubMed ID: 15761110
[TBL] [Abstract][Full Text] [Related]
4. CXCR3 requires tyrosine sulfation for ligand binding and a second extracellular loop arginine residue for ligand-induced chemotaxis.
Colvin RA; Campanella GS; Manice LA; Luster AD
Mol Cell Biol; 2006 Aug; 26(15):5838-49. PubMed ID: 16847335
[TBL] [Abstract][Full Text] [Related]
5. Synergistic induction of CXCL9 and CXCL11 by Toll-like receptor ligands and interferon-gamma in fibroblasts correlates with elevated levels of CXCR3 ligands in septic arthritis synovial fluids.
Proost P; Verpoest S; Van de Borne K; Schutyser E; Struyf S; Put W; Ronsse I; Grillet B; Opdenakker G; Van Damme J
J Leukoc Biol; 2004 May; 75(5):777-84. PubMed ID: 14996826
[TBL] [Abstract][Full Text] [Related]
6. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.
Lasagni L; Francalanci M; Annunziato F; Lazzeri E; Giannini S; Cosmi L; Sagrinati C; Mazzinghi B; Orlando C; Maggi E; Marra F; Romagnani S; Serio M; Romagnani P
J Exp Med; 2003 Jun; 197(11):1537-49. PubMed ID: 12782716
[TBL] [Abstract][Full Text] [Related]
7. Modelling of the membrane receptor CXCR3 and its complexes with CXCL9, CXCL10 and CXCL11 chemokines: putative target for new drug design.
Trotta T; Costantini S; Colonna G
Mol Immunol; 2009 Dec; 47(2-3):332-9. PubMed ID: 19800124
[TBL] [Abstract][Full Text] [Related]
8. Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function.
Colvin RA; Campanella GS; Sun J; Luster AD
J Biol Chem; 2004 Jul; 279(29):30219-27. PubMed ID: 15150261
[TBL] [Abstract][Full Text] [Related]
9. Alpha-chemokine receptors CXCR1-3 and their ligands in idiopathic inflammatory myopathies.
De Paepe B; De Keyzer K; Martin JJ; De Bleecker JL
Acta Neuropathol; 2005 Jun; 109(6):576-82. PubMed ID: 15937690
[TBL] [Abstract][Full Text] [Related]
10. Neutralization of IFN-inducible protein 10/CXCL10 exacerbates experimental autoimmune encephalomyelitis.
Narumi S; Kaburaki T; Yoneyama H; Iwamura H; Kobayashi Y; Matsushima K
Eur J Immunol; 2002 Jun; 32(6):1784-91. PubMed ID: 12115662
[TBL] [Abstract][Full Text] [Related]
11. I-TAC/CXCL11 is a natural antagonist for CCR5.
Petkovic V; Moghini C; Paoletti S; Uguccioni M; Gerber B
J Leukoc Biol; 2004 Sep; 76(3):701-8. PubMed ID: 15178708
[TBL] [Abstract][Full Text] [Related]
12. CXCR3, IP-10, and Mig are required for CD4+ T cell recruitment during the DTH response to HSV-1 yet are independent of the mechanism for viral clearance.
Molesworth-Kenyon S; Mates A; Yin R; Strieter R; Oakes J; Lausch R
Virology; 2005 Mar; 333(1):1-9. PubMed ID: 15708587
[TBL] [Abstract][Full Text] [Related]
13. CXCR3-binding chemokines in multiple myeloma.
Pellegrino A; Antonaci F; Russo F; Merchionne F; Ribatti D; Vacca A; Dammacco F
Cancer Lett; 2004 Apr; 207(2):221-7. PubMed ID: 15072832
[TBL] [Abstract][Full Text] [Related]
14. Optic neuritis: chemokine receptor CXCR3 and its ligands.
Sørensen TL; Roed H; Sellebjerg F
Br J Ophthalmol; 2004 Sep; 88(9):1146-8. PubMed ID: 15317705
[TBL] [Abstract][Full Text] [Related]
15. Chemokine receptor CXCR3: an unexpected enigma.
Liu L; Callahan MK; Huang D; Ransohoff RM
Curr Top Dev Biol; 2005; 68():149-81. PubMed ID: 16124999
[TBL] [Abstract][Full Text] [Related]
16. Elevated serum levels of the CXCR3 chemokine ITAC are associated with the development of transplant coronary artery disease.
Kao J; Kobashigawa J; Fishbein MC; MacLellan WR; Burdick MD; Belperio JA; Strieter RM
Circulation; 2003 Apr; 107(15):1958-61. PubMed ID: 12695288
[TBL] [Abstract][Full Text] [Related]
17. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes.
Kawada K; Sonoshita M; Sakashita H; Takabayashi A; Yamaoka Y; Manabe T; Inaba K; Minato N; Oshima M; Taketo MM
Cancer Res; 2004 Jun; 64(11):4010-7. PubMed ID: 15173015
[TBL] [Abstract][Full Text] [Related]
18. The relative activity of CXCR3 and CCR5 ligands in T lymphocyte migration: concordant and disparate activities in vitro and in vivo.
Stanford MM; Issekutz TB
J Leukoc Biol; 2003 Nov; 74(5):791-9. PubMed ID: 12960247
[TBL] [Abstract][Full Text] [Related]
19. Identification of CXCR3 receptor agonists in combinatorial small-molecule libraries.
Stroke IL; Cole AG; Simhadri S; Brescia MR; Desai M; Zhang JJ; Merritt JR; Appell KC; Henderson I; Webb ML
Biochem Biophys Res Commun; 2006 Oct; 349(1):221-8. PubMed ID: 16930533
[TBL] [Abstract][Full Text] [Related]
20. CXCR3 is involved in tubulointerstitial injury in human glomerulonephritis.
Segerer S; Banas B; Wörnle M; Schmid H; Cohen CD; Kretzler M; Mack M; Kiss E; Nelson PJ; Schlöndorff D; Gröne HJ
Am J Pathol; 2004 Feb; 164(2):635-49. PubMed ID: 14742268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
